Clarivate™

The Centre for Medicines Research (CMR) International

2020 CMR Pharmaceutical R&D Factbook



Pharma R&D in 2020: Staying ahead of the competition

Quickly see who's innovating, and in what areas, across pharma with the 2020 CMR Pharmaceutical R&D Factbook - an objective and reliable source for pharmaceutical benchmarks and trends. Whether you're assessing performance of your own program, the competition, your clients, or an investment opportunity, you need reliable, accurate benchmarks and industry data.

Answer questions you need for effective planning:

- How much is the industry forecasted to spend on R&D over the next 3 years?
- How much annual revenue is the industry reinvesting into R&D?
- How many blockbusters are set to lose patent exclusivity over the next 3 years?
- Which therapeutic areas have experienced positive growth in pipeline volume over recent years?
- Which therapeutic area has the highest investment?
- How is patient recruitment shifting across the industry?

The CMR Pharmaceutical R&D Factbook answers these questions and more. The Centre for Medicines Research, a wholly owned subsidiary of Clarivate, gathers and analyzes data from multiple proprietary data sets to provide authoritative and robust industry metrics for every stage of pharmaceutical development.

Use a well-established source of pharma and biotech metrics to better inform your strategy and planning:

- Gain an in-depth understanding of industry dynamics and trends.
- Determine how your organization performs against the market and gauge your productivity versus the competition.
- Identify the key differences between therapy areas and how to apply to your R&D strategies.
- Set performance targets that will motivate and challenge your business.
- Available as a "rich-data" Microsoft® PowerPoint® file, the slides present results in a clear, easily understood format, perfect for presentation. Each slide is accompanied by a succinct explanation of the methodology used and the definitions applied.
- Includes over 75 robust charts, tables and graphs which are exportable to other applications. Simply copy/paste the graphics or slides into your own presentation.
- Each interactive chart or graph enables you to drill down to the underlying data with the click of a mouse – and analyze the figures behind the trend.
- The rich-data enterprise PowerPoint is accessible to unlimited users within your organization.

Start using a trusted source of industry benchmarks today. **Order your 2020 Factbook now!**

About the Centre of Medicines Research (CMR) International

CMR, a leader in global pharmaceutical R&D performance measures, brings together data sets from prominent sources to provide objective information and insights into global pharmaceutical R&D performance. For over 20 years, CMR International has worked with the leading global pharmaceutical companies to assess R&D productivity and provide insights into industry trends which are used to strengthen the planning and effectiveness of R&D.

Since 2003, CMR International has published the Pharmaceutical R&D Factbook, an annual report designed to equip the Pharmaceutical R&D sector with a reliable quotable source of key reference metrics and an insight into current industry trends.

The CMR International performance metrics programs on which this report is based cover every aspect of pharmaceutical R&D and are broken into three key areas – Global R&D, Global Clinical, and Asia Pacific. CMR programs are ongoing and focused on key issues, with datasets built on over 20 years of rigorous development. The datasets have the unique depth and historical context to uncover reliable industry trends, set in context against the changing marketplace.
To find out more about CMR International, visit: **clarivate.com/benchmarking**

CMR International 2020 Pharmaceutical R&D Factbook -- Contents

List of figures

Chapter 4. Success Rates

1. Probability of success to market for active substances
2. Probability of success to market from key milestones: changes over time
3. Probability of success to market by origin
4. Predicted number of active substances required at each stage to achieve one marketed active substance

Chapter 5. Cycle Times

1. R&D key milestones
2. Development time for new molecular entities first launched onto the world market 2010-2019
3. Trend in actual clinical development time for lead projects submitted 2010-2018
4. Composite median interval duration for lead projects 2014-2018
5. Trend in median interval durations for lead projects between 2010-2018

Chapter 6. Regional Comparisons

1. Regional distribution of total R&D expenditure in 2019
2. Region of first launch for new molecular entities 2010-2019
3. Median approval times for new active substances approved for three major regulatory agencies between 2009-2019
4. Regulatory approval times from date of submission to approval for new active substances approved between 2013-2017
5. Time between first world approval and submission in emerging market countries for new active substances approved between 2013-2017
6. Number of expedited and standard new active substance approvals 2008-2013 compared with 2014-2019
7. Median time in roll out to emerging market countries for new active substances approved between 2013-2017

Chapter 7. Therapeutic Area Focus

1. Total R&D expenditure in 2019 by therapeutic area
2. Total R&D expenditure in 2019 by therapeutic area by phase
3. Proportion of first new molecular entity launches in 2019 by therapeutic area
4. Change in number of lead projects in development for first launch between 2017-2019 by therapeutic area
5. Therapeutic area diversification between 2017-2019 by company size
6. Probability of success to market by therapeutic area (1) CMR success rates methodology
7. Probability of success to market by therapeutic area (2) CMR success rates methodology
8. Composite median interval durations for lead and parallel projects between 2014-2018 by therapeutic area
9. Median approval times for new active substances between 2014-2019 by therapeutic area

Chapter 8. Biopharmaceutical Focus

1. Proportion of R&D expenditure in 2018 and 2019 by active substance type
2. Proportion of ethical pharmaceutical sales in 2019 by active substance type
3. Number of first NME launches between 2009-2019 by active substance type
4. Proportion of NBE active substances in development between 2015-2019 by company size
5. Proportion of licensed-in or acquired active substances in development in 2015 and 2019 by active substance type
6. Probability of success to market by active substance type
7. Composite median interval durations for lead projects between 2014-2018 by active substance type

Chapter 9. Clinical Functions

1. Clinical study median interval durations by study phase in 2018
2. Comparisons of the change in clinical study median interval durations between 2014 and 2018 by study phase

Chapter 10. Patents

1. Number of pharmaceutical patent applications and granted patents for 4 major patent issuing authorities 2009-2019
2. Total and new compound WO, EP or US patent document filings 2011-2019
3. Most popular targets by number of 'new entrants' since 2017 for the industry
4. Most popular targets by number of 'new entrants' since 2017 for the 30 most innovative companies
5. Therapy area focus of the most popular emerging targets since 2017

Chapter 11. Global Generics Market

1. Number of ANDA final approvals in each year between 2017-2019 by country of origin
2. Number of ANDA approvals for Indian generic companies between 2010-2019
3. Exposure of products to Paragraph IV challenges in US between 2013-2019
4. Total Paragraph IV challenges by country (count of single filing per group)
5. Number of products predicted to lose exclusivity in US between 2020-2026
6. Current experience of generic API manufacturers with regard to supplying the regulated markets
7. Number of European Certificates of Suitability (COS) granted between 2010-2019 by location of company headquarters
8. Number of US DMF granted each year between 2010-2019 by location of company headquarters
9. API Plants inspected by FDA in each year between 2011-2019 by location of company headquarters

Stop using old benchmarks! Get the authoritative source for pharma metrics and trends – all in one convenient report. **Purchase your copy now!**

About Clarivate

Clarivate™ is a global leader in providing trusted information and insights to accelerate the pace of innovation. We offer subscription and technology-based solutions coupled with deep domain expertise that cover the entire lifecycle of innovation – from foundational research and ideas to protection and commercialization. Today, we're setting a trail-blazing course to help customers turn bold ideas into life-changing inventions. Our portfolio consists of some of the world's most trusted information brands, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. For more information, please visit clarivate.com.

clarivate.com